In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Role of cardiac resynchronization therapy in optimizing the recovery of left ventricular function in a patient with peripartum cardiomyopathy and left bundle branch block

Session Poster Session 1

Speaker Hasan Al Farhan

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Resynchronization Therapy
  • Session type : Poster Session
  • FP Number : P615

Authors : H A Farhan (Baghdad,IQ), G F Haji (Baghdad,IQ), G M Mahmood (Baghdad,IQ), I F Yaseen (Baghdad,IQ)

H A Farhan1 , G F Haji1 , G M Mahmood1 , I F Yaseen1 , 1Baghdad Medical City, Cardiology - Baghdad - Iraq ,


Peripartum cardiomyopathy (PPCM) is presenting at the end of pregnancy or within 6 months postpartum with left ventricular dysfunction with EF <45%. Incidence is estimated to be 1:1000-4000. Rates of recovery ranging from 29 – 72% and mortality 25%.Management including medical therapy, cardiac devices, and heart transplant. Available published data showing three reported cases of PPCM with LBBB for whom Cardiac resynchronisation therapy [CRT] was implanted

Case Presentation
A 36-year-old woman, presented 3 months postpartum with severe dyspnea (NYHA III), she has non relevant past medical history.  Echocardiography showed LVEF 25% and severe MR, diagnosed as PPCM

Medical therapy was started with carvedilol, ramipril, indapamide, and spironolactone. After 17 months, despite the maximum tolerated dose of medical therapy, LV function did not improve and her symptoms worsen. Her ECG showed LBBB. Post CRT implantation, her LVEF recovers after 3 months, reaching 60% at 7 month follow up with dramatic improvement in her symptoms (NYHA I).

Conclusion and implication for clinical practice
CRT could be considered for optimizing LV function recovery in patients with PPCM despite optimal medical therapy. Comparing with the other two published cases, first case was refractory for medical therapy for 9 years with EF 28%, reached 55% six-month after CRT. Second case, her EF was 25% over 6 years, then 45% six-month post CRT. According to the current guideline in heart failure, eligibility for CRT should be evaluated after 6 months, however, the possibility of PPCM recovery make the early decision of CRT challenging. Moreover, the current data regarding use of CRT in PPCM is limited and there is a lack of precise follow up. Therefore, we need focus and orientation regarding this topic to bridge the gap of evidence to determine predictor factors for optimum time of CRT implantation in patients who are refractory to medical management

Follow-up data














ECG QRS [msec] 140 120 120 120 80 80

QT [msec]

280 360 400 400 340 360
Echo LVEDD [mm] 59 68 60 54 ------- -------
LVESD [mm] 52 59 45 40 ------- -------
GLS% ------- -10 -9 ------- -12 -13
EF% 25 28 40 39




52 60

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are